Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 288-292, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rudolph, D. L.
Right arrow Articles by Lal, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rudolph, D. L.
Right arrow Articles by Lal, R. B.

Clinical Chemistry, Vol 39, 288-292, Copyright © 1993 by American Association for Clinical Chemistry

Discrimination of human T-lymphotropic virus type-I and type-II infections by synthetic peptides representing structural epitopes from the envelope glycoproteins

DL Rudolph and RB Lal
Retrovirus Diseases Branch, Centers for Disease Control, Atlanta, GA 30333.

Synthetic peptides representing the immunodominant structural motifs of the envelope region of human T-lymphotropic virus types I (HTLV-I) (Env- 1(191-214) and Env-5(242-257)) and II (HTLV-II) (Env-20(85-102 and Env- 2(187-209)) were used to develop an enzyme immunoassay that could discriminate between HTLV-I and HTLV-II. Serum specimens from individuals whose infections were confirmed and typed by means of the polymerase chain reaction (PCR) were used to determine the sensitivity and specificity of the new assay. When 73 PCR-confirmed HTLV-I specimens were tested with the HTLV-I peptides, the absorbance values for 71 (97.3%) were at least two times higher than the values obtained with the HTLV-II peptides; these samples thus were classified as HTLV- I. Two specimens reacted with all the peptides and, therefore, could not be typed. Conversely, when 59 PCR-confirmed HTLV-II specimens were tested with the HTLV-II peptides, 55 (93%) produced high absorbance values and were typed as HTLV-II; 4 specimens could not be typed. None of the specimens was incorrectly typed; hence, the specificity of this assay was 100%. When this assay was compared with other HTLV immunoassays, the degrees of sensitivity and specificity were similar. The main advantage of this new assay is that synthetic peptides representing variant sequences can easily be added as new variant HTLV strains are identified.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Virol.Home page
Y. Peng, F.-c. Lin, P. H. Verardi, L. A. Jones, and T. D. Yilma
Lower Levels of Gamma Interferon Expressed by a Pseudotyped Single-Cycle Simian Immunodeficiency Virus Enhance Immunogenicity in Rats
J. Virol., February 15, 2009; 83(4): 1592 - 1601.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
J. Dorn, S. Masciotra, C. Yang, R. Downing, B. Biryahwaho, T. D. Mastro, J. Nkengasong, D. Pieniazek, M. A. Rayfield, D. J. Hu, et al.
Analysis of Genetic Variability within the Immunodominant Epitopes of Envelope gp41 from Human Immunodeficiency Virus Type 1 (HIV-1) Group M and Its Impact on HIV-1 Antibody Detection
J. Clin. Microbiol., February 1, 2000; 38(2): 773 - 780.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.